Drug intelligence / Profile preview

U-CH3

Development stage
Preclinical
Lead developer
University of Florida Center for Natural Products, Drug Discovery and Development
Modality
Small Molecules
01

Overview

U-CH3 is a small molecule ureido-substituted benzene sulfonamide (USB) that acts as a potent and selective inhibitor of the tumor-associated carbonic anhydrase isoforms IX (CA IX) and XII (CA XII). It functions by binding to the catalytic zinc ion within the enzyme's active site via its sulfonamide moiety and interacting with a "selective pocket" (specifically residue 131), which provides significant selectivity over the off-target cytosolic isoform CA II. In preclinical breast cancer models, U-CH3 has demonstrated the ability to inhibit cell growth, migration, and invasion, particularly in triple-negative breast cancer (TNBC) and ER-positive cell lines. Research indicates a notable disconnect between its high affinity for purified recombinant proteins and the significantly higher concentrations required to achieve growth inhibition in intact cells, suggesting that its anti-proliferative effects may involve mechanisms beyond simple exofacial CA inhibition.

Other names
ureido-substituted benzene sulfonamide
02

Targets

CA12 (Carbonic anhydrase XII)CA2 (Carbonic Anhydrase 2)

Beyond the preview

Go deeper on U-CH3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on U-CH3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call